Therefore, the development of GLP-1-based polyagonists (bi- and triagonists) that activate different incretin receptors in one molecule to improve efficacy while maintaining an adequate tolerability and safety profile, is a milestone in T2D and obesity management and treatment. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.